welcome
Reuters

Reuters

Health

Health

J&J to buy Intra-Cellular Therapies for $14.6 billion

Reuters
Summary
Nutrition label

76% Informative

Johnson & Johnson said on Monday it would buy drugmaker Intra-Cellular Therapies for about $14.6 billion .

The deal is the latest in a string of acquisitions by J&J as it looks to drive growth beyond 2025 .

Last year , the company acquired Numab 's skin disorder drug for $1.25 billion , and spent $850 million to buy Proteologix .

VR Score

85

Informative language

91

Neutral language

26

Article tone

formal

Language

English

Language complexity

50

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links